BHA have released their findings in the Al Zarooni case:
Result and Reasons of a Disciplinary Panel hearing (Mahmood Al Zarooni)
The Disciplinary Panel of the British Horseracing Authority ("BHA") held an Inquiry on 25 April 2013 into the blood samples taken on 9 April 2013 from various horses at the training yard of Mahmood Al Zarooni, a licensed trainer, to establish whether or not he was in breach of the following Rules of Racing:
1. Allegations
1.1 Whether breaches of Rule (C)50 and/or Rule (C)55 have been committed by Al Zarooni by virtue of the samples taken from all or any of the following horses (being horses in the care or control of Al Zarooni) on 9 April 2013 testing positive for the prohibited substance Ethylestranol:
(a) GHOSTFLOWER (IRE)
(b) SWEET ROSE
(c) VALLEY OF QUEENS (IRE)
(d) FAIR HILL
(e) DESERT BLOSSOM (IRE)
(f) CERTIFY (USA)
(g) ORKNEY ISLAND
1.2 Whether breaches of Rule (C)50 and/or Rule (C)55 have been committed by Al Zarooni by virtue of the samples taken from all or any of the following horses (being horses in the care or control of Al Zarooni) on 9 April 2013 testing positive for the prohibited substance Stanozolol:
(a) OPINION POLL (IRE)
(b) ARTIGIANO (USA)
(c) RESTRAINT OF TRADE (IRE)
(d) BATHRAT AMAL (JPN)
1.3 Whether Al Zarooni is in breach of Rule (C)13 by virtue of his failure to keep a 'Record of Treatment' for all or any of the following (namely the administration of Ethylestranol) which included the information listed in Rules (C)13.2.1 to (C)13.2.6 for such treatment:
(a) GHOSTFLOWER (IRE)
(b) SWEET ROSE
(c) VALLEY OF QUEENS (IRE)
(d) FAIR HILL
(e) DESERT BLOSSOM (IRE)
(f) CERTIFY (USA)
(g) ORKNEY ISLAND
(h) COMITAS
(i) SASHIKO
(j) VACATIONER
1.4 Whether Al Zarooni is in breach of Rule (C)13 by virtue of his failure to keep a 'Record of Treatment' for all or any of the following (namely the administration of Stanozolol) which included the information listed in Rules (C)13.2.1 to (C)13.2.6 for such treatment:
(a) OPINION POLL (IRE)
(b) ARTIGIANO (USA)
(c) RESTRAINT OF TRADE (IRE)
(d) BATHRAT AMAL (JPN)
(e) TEARLESS
1.5 Whether Al Zarooni caused or allowed to be administered Ethylestranol, a prohibited substance, to all or any of the following horses under his care:
(a) GHOSTFLOWER (IRE)
(b) SWEET ROSE
(c) VALLEY OF QUEENS (IRE)
(d) FAIR HILL
(e) DESERT BLOSSOM (IRE)
(f) CERTIFY (USA)
(g) ORKNEY ISLAND
(h) COMITAS
(i) SASHIKO
(j) VACATIONER
and as a result breached Rule (A)30 by acting in a manner that was prejudicial to the integrity, proper conduct and/or good reputation of horseracing in Great Britain.
1.6 Whether Al Zarooni caused or allowed to be administered Stanozolol, a prohibited substance, to all or any of the following horses under his care:
(a) OPINION POLL (IRE)
(b) ARTIGIANO (USA)
(c) RESTRAINT OF TRADE (IRE)
(d) BATHRAT AMAL (JPN)
(e) TEARLESS
and as a result breached Rule (A)30 by acting in a manner that was prejudicial to the integrity, proper conduct and/or good reputation of horseracing in Great Britain.
2. Admissions
2.1 At the outset of the hearing Al Zarooni admitted all the alleged breaches of the Rules and apologised for his actions.
2.2. The Panel received submissions from Graeme McPherson QC on behalf of the BHA regarding the background facts of the case. All of the evidence submitted by the BHA was accepted without challenge by Al Zarooni. Mr McPherson also addressed the Panel on the features of the case that should be taken into account when approaching the question of penalty.
2.3 Al Zarooni briefly addressed the Panel on the background to the issues.
3. Background Facts
3.1 On 9 April 2013 the BHA conducted a 'testing in training' visit to Godolphin's Moulton Paddocks Stables in Newmarket where Al Zarooni was responsible for just over 200 horses. There had been issues identified in relation to medication records during a previous visit in 2010 and two of Al Zarooni's horses had post-race positive tests in 2012; on both occasions for painkillers.
3.2 The testing visit was led by Dr Lynn Hillyer, a Veterinary Officer employed by the BHA as their Veterinary Advisor (Medication Control).
3.3 The visit itself was uneventful and samples were taken from 45 horses. Al Zarooni was still in Dubai following the Dubai World Cup Carnival but his staff assisted the BHA. Mr Charlie Appleby, the yard manger, accompanied the BHA staff and Mr Simon Crisford, Racing Manager to Godolphin, arrived during the sampling to check what was happening. The Medication Books were assessed and in the view of Dr Hillyer they appeared 'in good order' with the overall use of medication seeming to have decreased compared with a review three years previously.
3.4 On 16 April 2013 HFL Sport Science, the laboratory responsible for conducting the sample testing, rang Dr Hillyer to report four unusual screening findings for stanozolol. Verbal authorisation was given to proceed to confirmatory analysis. Later that day, seven further samples were reported as screening positive for ethylestranol. Confirmatory analysis was authorised for these further samples. All eleven samples were confirmed as positive findings.
3.5 In the light of the positive findings, a meeting was arranged the following morning with Mr Crisford. Present at the meeting from the BHA were Dr Hillyer and Mr Stuart Williams, a BHA Investigating Officer. Mr Crisford was informed of the positive findings and was requested to make enquiries to ascertain if a source of the drugs could be identified.
3.6 At 3pm the same afternoon a further meeting was held with Al Zarooni present. Mr Paul Bittar, the BHA Chief Executive also attended as an observer.
3.7 At the meeting Al Zarooni admitted being responsible for the administration of Stanasol (which contains stanozolol) on 14 March 2013 to the four horses that returned positive samples for stanozolol. He also admitted being responsible for the administration of Nitrotain to seven horses (which contains ethylestranol), between 14 March and 7 April 2013 to those horses which returned positive samples for ethylestranol . At the interview Al Zarooni produced the box of Nitrotain which was the source of the ethylestranol and handed over the unused Nitrotain that had not yet been dispensed together with a list of the horses that had received the medication. He confirmed he no longer held any more stock of Stanasol.
3.8 Al Zarooni informed the BHA that he had also administered Stanasol to one additional horse, and Nitrotain to three further horses which had not been tested at the initial visit on 9 April 2013.
3.9 Al Zarooni explained at interview that his knowledge of the drug came from working in Dubai where use of anabolic steroids in training is permitted. He told the Investigating Officer that he thought the drug could be used if the horse was not racing. Al Zarooni confirmed that he had not recorded the administration of any of the anabolic steroids in the stable's Medication Books. He could offer no explanation for this omission.
3.10 At the hearing Al Zarooni admitted, when questioned by the Panel, that he personally brought the anabolic steroids into the UK in his luggage when returning from Dubai. In relation to the administration of Stanasol, he informed the Panel that on 14 March 2013 he made up five unmarked syringes each containing 4ml of the drug from his bottle of the drug. He then drove to Moulton Paddocks Stables and passed the syringes out of his car window to an unqualified veterinary assistant, Sharif Mahboob, and asked him to give the drugs to five horses which he listed on a piece of paper. All five horses were under veterinary care at the time in respect of musculoskeletal problems and in one case, colic. Al Zarooni said he thought the drug would help improve the horses' condition.
3.11 In relation to the Ethylestranol, Al Zarooni told the Panel that he asked his stable staff to include this medication, which was in paste form, to be included in the feed of a number of horses to stimulate their appetite.
3.12 Al Zarooni explained to the Panel that in Dubai anabolic steroid drugs are given to horses in training. Having received the drug, the horses are only allowed to race following elapse of the 28 day withdrawal period for the drug.
4. Stanozolol and Ethylestranol
4.1 The Panel received written evidence from Dr Hillyer as to the effects of anabolic steroids in horses. The evidence was not challenged by Al Zarooni.
4.2 Dr Hillyer's evidence confirmed that the anabolic steroid drugs Stanozolol and Ethylestranol have no licensed veterinary formulation in Great Britain. Both drugs have little or no therapeutic indication in horses. Each of the drugs have anabolic actions on the body; stimulating metabolism.
4.3 Her statement set out the references in the Rules of Racing which make it explicit that anabolic steroids are prohibited substances and as such should never be present in a horse that is under the care or control of a licensed or permitted trainer.
4.4 As to their effect, Dr Hillyer acknowledged that at the present time it is scientifically unproven whether anabolic steroids do in fact enhance equine performance; the research simply has not been done. That said Dr Hillyer asserted in her evidence that since anabolic steroids have clear effects on body weight and muscle mass it is likely that they will enhance performance in horses in a manner similar to human athletes.
(cont)...